Fenofibrate
Fenofibrate is a synthetic lipid-modifying agent in the fibrate class, used clinically to lower elevated triglycerides and, in some settings, to improve mixed dyslipidemia.
Fenofibrate is a synthetic lipid-modifying agent in the fibrate class, used clinically to lower elevated triglycerides and, in some settings, to improve mixed dyslipidemia. It is a prodrug that is converted in vivo to fenofibric acid, the active metabolite. Its principal pharmacologic action is activation of peroxisome proliferator-activated receptor alpha (PPAR-α), which regulates genes involved in fatty acid oxidation, lipoprotein metabolism, and triglyceride clearance.
Beyond its established therapeutic role, fenofibrate continues to be studied in broader biomedical contexts because of its effects on lipid handling, inflammation, and cellular stress pathways. In recent research, it has also appeared in computational drug-repurposing workflows and environmental monitoring studies, reflecting both its clinical relevance and its persistence as a pharmaceutically active compound in the environment.
Where the papers sit
11 papers from the last 6 months study fenofibrate directly · updated from PubMed 5 Oct 2026
Study type 0 clinical trials · 3 observational · 7 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
Clinical Uses and Outcomes
Fenofibrate use is extending beyond lipid lowering into prevention of recurrent hypertriglyceridemic pancreatitis and adjunctive treatment of primary biliary cholangitis. Reports include pregnancy managed with plasmapheresis and fenofibrate, prolonged therapy after pancreatitis, and improved transplant-free survival with add-on treatment. Real-world analysis also examines sight-threatening diabetic retinopathy, while computational work nominates fenofibrate among potential sepsis drugs. Evidence remains largely observational, case-based or exploratory rather than definitive.
5 papers · 45.5%
-
Quality Control Analysis
Fenofibrate tablet testing is moving toward sensitive, reproducible reversed-phase HPLC and UHPLC assays. Isocratic methods emphasize short run times, recovery and low coefficients of variation for routine quality control. Quality-by-Design integration is being used to strengthen method development and validation. The shared goal is reliable quantitative release testing rather than new therapeutic application.
2 papers · 18.2%
-
Others — Drug Delivery and Safety
Formulation work targets better fenofibrate solubility, dissolution and sustained ocular delivery through cyclodextrin inserts, binding agents and nanoemulsions. Proton NMR is being used to track drug redistribution during nanoemulsion destabilization. A separate pemafibrate analysis combines adverse-event data with animal experiments to assess risk. The cluster therefore lacks one unified direction, spanning delivery optimization and fibrate safety.
4 papers · 36.4%
Fenofibrate is repositioned as a candidate therapy for sepsis-associated cellular senescence
The sepsis study using bioinformatics, machine learning, and in vivo and in vitro models treats fenofibrate not as a lipid-lowering intervention or formulation target, but as a potential drug directed at senescence-related molecular abnormalities in sepsis. The study instead identifies fenofibrate through interactions with sepsis-associated hub proteins, including CDKN1C, BCL2, and SMAD3, giving it a proposed role in cellular-senescence-driven organ dysfunction rather than the lipid disorders and drug-delivery problems addressed elsewhere in the set. This expands fenofibrate into a senescence-targeted sepsis research direction, although the abstract does not establish clinical efficacy 42219284May.
Papers
The 11 papers from the last 6 months that study fenofibrate directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Clinical Uses and Outcomes (5)
- Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis: A long-term retrospective follow-up study. Medicine · 2 Oct 2026 PMID 42826301
- Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. The Journal of clinical endocrinology and metabolism · 7 Sept 2026 PMID 42702803
- Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
- Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients. European journal of gastroenterology & hepatology · 29 May 2026 PMID 42214018
- A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. The American journal of case reports · 28 May 2026 PMID 42204798
Quality Control Analysis (2)
- Development and Validation of Isocratic RP-UHPLC Method for Assay of Fenofibrate Tablet. Biomedical chromatography : BMC · 28 Jul 2026 PMID 42517867
- Development and validation of a QbD-integrated sensitive RP-HPLC method for quantitation of fenofibrate: an application in quality control. Analytical methods : advancing methods and applications · 7 May 2026 PMID 42093465
Others — Drug Delivery and Safety (4)
- Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? The AAPS journal · 10 Sept 2026 PMID 42717179
- Polymer-free electrospun hydroxypropyl-β-cyclodextrin inserts for sustained ocular delivery of fenofibrate: a novel approach for management of posterior segment ocular disease. International journal of pharmaceutics · 28 Aug 2026 PMID 42665196
- Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379788
- Visualizing the Spatiotemporal Redistribution of Drugs in Destabilizing Nanoemulsions: A Quantitative Solution 1H NMR Approach. Molecular pharmaceutics · 9 Jun 2026 PMID 42260710
By study type
Observational studies and case reports (3)
- Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis: A long-term retrospective follow-up study. Medicine · 2 Oct 2026 PMID 42826301
- Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients. European journal of gastroenterology & hepatology · 29 May 2026 PMID 42214018
- A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. The American journal of case reports · 28 May 2026 PMID 42204798
Preclinical: animal, cell and lab studies (7)
- Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? The AAPS journal · 10 Sept 2026 PMID 42717179
- Polymer-free electrospun hydroxypropyl-β-cyclodextrin inserts for sustained ocular delivery of fenofibrate: a novel approach for management of posterior segment ocular disease. International journal of pharmaceutics · 28 Aug 2026 PMID 42665196
- Development and Validation of Isocratic RP-UHPLC Method for Assay of Fenofibrate Tablet. Biomedical chromatography : BMC · 28 Jul 2026 PMID 42517867
- Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379788
- Visualizing the Spatiotemporal Redistribution of Drugs in Destabilizing Nanoemulsions: A Quantitative Solution 1H NMR Approach. Molecular pharmaceutics · 9 Jun 2026 PMID 42260710
- Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
- Development and validation of a QbD-integrated sensitive RP-HPLC method for quantitation of fenofibrate: an application in quality control. Analytical methods : advancing methods and applications · 7 May 2026 PMID 42093465
Unclassified: not yet indexed with MeSH (1)
- Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. The Journal of clinical endocrinology and metabolism · 7 Sept 2026 PMID 42702803
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.